SSEA-1 Antibody (MC-480) [Alexa Fluor® 647]

SSEA‑1 was detected in immersion fixed D3 mouse embryonic stem cell line using Mouse Anti-Human/ Mouse SSEA‑1 Alexa Fluor® 647‑conjugated Monoclonal Antibody (Catalog # IC2155R; red) at 10 µg/mL for 3 hours at room temperature. Cells were counterstained with DAPI (blue). Specific staining was localized to cytoplasm and cell surfaces. View our protocol for Fluorescent ICC Staining of Stem Cells on Coverslips.

D3 mouse embryonic stem cell line was stained with Mouse Anti-Human/Mouse SSEA-1 Alexa Fluor® 647-conjugated Monoclonal Antibody (Catalog # FAB2155R, filled histogram) or isotype control antibody (IC015R, open histogram). View our protocol for Staining Membrane-associated Proteins.

Product Discontinued

SSEA-1 Antibody (MC-480) [Alexa Fluor® 647] Summary

• Immunogen: F9 mouse teratocarcinoma stem cells
• Specificity: Detects human and mouse SSEA-1.
• Source: N/A
• Isotype: IgM
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: IgM-specific Affinity-purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 -1.0 ug/10^6 cells
  • Immunocytochemistry 5-25 ug/mL

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SSEA-1 Antibody (MC-480) [Alexa Fluor® 647]

• alpha-(1,3)-fucosyltransferase
• CD15
• EC 2.4.1
• EC 2.4.1.-
• EC 2.4.1.65
• ELAM-1 ligand fucosyltransferase
• ELFT
• FCT3AELAM ligand fucosyltransferase
• fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
• Fucosyltransferase 4
• Fucosyltransferase IV
• FUC-TIV
• FucT-IV
• FUTIV
• Galactoside 3-L-fucosyltransferase
• Lewis X
• LeX
• SSEA1
• SSEA-1
• stage-specific embryonic antigen 1

Background

Stage-Specific Embryonic Antigen-1 (SSEA-1), an antigenic epitope defined as a Lewis x carbohydrate structure, is expressed during early mouse embryogenesis on murine embryonal carcinoma cells (EC), murine embryonic stem cells (ES), and murine and human germ cells. Expression of SSEA-1 is down-regulated following differentiation of murine EC and ES cells. In contrast, the differentiation of human EC and ES cells is accompanied by an increase in SSEA-1 expression (1, 2).

1. Solter, D. and Knowles, B.B. (1978) Proc. Natl. Acad. Sci. USA 75:5565.
2. Fox, N. et al. (1983) Cancer Res. 43:669.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.